Phaseline

Targets › ACHE

ACHE (Acetylcholinesterase): drug programs, companies and trials

21 programs from 19 companies in 24 trials: 13 Phase 2, 5 Phase 1, 4 Phase 4, 2 Phase 3; Neurology, Cardiovascular, Other; next expected readout Dec 2026.

Hydrolyzes rapidly the acetylcholine neurotransmitter released into the synaptic cleft allowing to terminate the signal transduction at the neuromuscular junction. Role in neuronal apoptosis. (UniProt, P22303)

Open in Phaseline: the race on ACHE, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Wanbangde Pharmaceutical GroupHuperzine A Controlled-Release Tablets
Acetylcholinesterase inhibitor
ACHEPhase 4Cognitive Impairment After Brain Injury; Alzheimer DementiaDec 2026
Alpha CognitionBenzgalantamine
Acetylcholinesterase inhibitor
ACHEPhase 4Alzheimer DiseaseApr 2027
Virginia Commonwealth UniversityGalantamine
Acetylcholinesterase inhibitor
ACHEPhase 4Dementia With Lewy BodiesNov 2029
University of Sao PauloDonepezil
Acetylcholinesterase inhibitor
ACHEPhase 4Tinnitus–
Assistance Publique - Hôpitaux de ParisDonepezil
Acetylcholinesterase inhibitor
ACHEPhase 3Alzheimer Disease, Early Onset–
James J. Peters Veterans Affairs Medical CenterNeostigmine
Acetylcholinesterase inhibitor
ACHEPhase 3Spinal Cord Injuries–
University of Vermont Medical CenterPyridostigmine Bromide
Acetylcholinesterase inhibitor
ACHEPhase 2Parkinson DiseaseDec 2026
Mayo Clinicpyridostigmine
Acetylcholinesterase inhibitor
ACHEPhase 2Postural Tachycardia SyndromeFeb 2027
Assiut UniversityNeostigmine
Acetylcholinesterase inhibitor
ACHEPhase 2Postdural Puncture Headache (PDPH)Mar 2027
Northwell HealthGalantamine Hydrobromide
Acetylcholinesterase inhibitor
ACHEPhase 2Spinal Cord InjuryAug 2027
Supernus PharmaceuticalsHuperzine A (SPN-817)
Acetylcholinesterase inhibitor
ACHEPhase 2Focal Onset Seizures; EpilepsyAug 2027
Duke UniversityDonepezil
Acetylcholinesterase inhibitor
ACHEPhase 2OsteoporosisSep 2027
Brigham and Women's HospitalPyridostigmine
Acetylcholinesterase inhibitor
ACHEPhase 2ME/CFSSep 2027
Shanghai Yueyang Integrated Medicine HospitalGalantamine
Acetylcholinesterase inhibitor
ACHEPhase 2Acute Ischemic Stroke AISSep 2028
Washington University School of MedicineRivastigmine
Cholinesterases; ACHE & BCHE inhibitor
BCHE, ACHEPhase 2Anticholinergic ToxicityNov 2028
VA Connecticut Healthcare SystemDonepezil
Acetylcholinesterase inhibitor
ACHEPhase 2Alcohol Use Disorder–
Stefan Holubar MD MS FACS, FASCRSPyridostigmine Bromide
Acetylcholinesterase inhibitor
ACHEPhase 2Postoperative Ileus–
Supernus PharmaceuticalsBIS-001-ER
acetylcholinesterase inhibitor
ACHEPhase 1Focal Impaired Awareness SeizuresDec 2026
Vanderbilt University Medical CenterGalantamine
Acetylcholinesterase inhibitor
ACHEPhase 1Endothelial Dysfunction; Postural Tachycardia SyndromeMay 2027
Vanderbilt University Medical CenterPyridostigmine
Acetylcholinesterase inhibitor
ACHEPhase 1Postural Tachycardia SyndromeJun 2027
Inventage Lab.IVL3003
Donepezil long-acting injection
ACHEPhase 1Alzheimer Disease–

Conditions

Postural Tachycardia Syndrome (3) Alzheimer Disease (2) Postdural Puncture Headache (PDPH) (1) Endothelial Dysfunction (1) Osteoporosis (1) Alcohol Use Disorder (1) ME/CFS (1) Cognitive Impairment After Brain Injury (1) Alzheimer Dementia (1) Anticholinergic Toxicity (1) Spinal Cord Injuries (1) Postoperative Ileus (1)

Modalities

small molecule (14), protein or peptide (3), mixed (2), antibody (1)

Companies

Vanderbilt University Medical Center (2) Supernus Pharmaceuticals (2) Mayo Clinic (1) Assiut University (1) Duke University (1) VA Connecticut Healthcare System (1) Brigham and Women's Hospital (1) Wanbangde Pharmaceutical Group (1) Washington University School of Medicine (1) James J. Peters Veterans Affairs Medical Center (1) Stefan Holubar MD MS FACS, FASCRS (1) Shanghai Yueyang Integrated Medicine Hospital (1) Inventage Lab. (1) Northwell Health (1) University of Sao Paulo (1) Virginia Commonwealth University (1) Assistance Publique - Hôpitaux de Paris (1) Alpha Cognition (1) University of Vermont Medical Center (1)

Related targets

BCHE (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.